IRIS trial update from ASH

[Guest guest]

For newbies who may not know, IRIS is the name of the trial that first

studied newly diagnosed patients on Gleevec and every year at the ASH

meeting, we get a follow up on how these patients are doing.

They now have 6 years of data to report and this abstract gives the

information.

http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5354 & terms=

I'm very excited to say that for patients who have been on Gleevec for

between 5 and 6 years, only 0.4% have lost their response and 0% of

them have progressed to accelerated or blast phase.

The abstract also says that no new serious adverse events have been

found in the last year, meaning that Gleevec continues to be a safe

drug over long term use (if you consider 6 years long term

Take care,

Tracey

[Guest guest]

Also an article in Blood on the 6 years IRIS results.

http://tinyurl.com/2zzl2s

I put a link to the abstract, feel free to ask if you want the full

article. Thanks Tracey for the info on the ASH papers. I like the

thing about the time to CCR not being that relevant, hope it's the

same for MMR BTW I got my last pcr this week and it's still going

down, -2.8 log, I am staying on 400mg .

Cheers,

Marcos.

On Nov 11, 2007 8:01 AM, Tracey <traceyincanada@...> wrote:

>

>

>

>

> For newbies who may not know, IRIS is the name of the trial that first

> studied newly diagnosed patients on Gleevec and every year at the ASH

> meeting, we get a follow up on how these patients are doing.

>

> They now have 6 years of data to report and this abstract gives the

> information.

> http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5354 & terms=

>

> I'm very excited to say that for patients who have been on Gleevec for

> between 5 and 6 years, only 0.4% have lost their response and 0% of

> them have progressed to accelerated or blast phase.

>

> The abstract also says that no new serious adverse events have been

> found in the last year, meaning that Gleevec continues to be a safe

> drug over long term use (if you consider 6 years long term

>

> Take care,

> Tracey

>

>

--

Marcos Perreau Guimaraes

Suppes Brain Lab

Ventura Hall - CSLI

Stanford University

220 Panama street

Stanford CA 94305-4101

650 614 2305

650 630 5015 (cell)

marcospg@...

montereyunderwater@...

www.stanford.edu/~marcospg/

[Guest guest]

Hi Marcos,

That's great news about your PCR continually heading downwards. I'm

not sure that there's a big difference in survival between people who

are MMR over those that are just CCR though. Of course we all want

to be as good as we can be, but how important is it to be at 3 logs?

I'll see what I can find in the ASH abstracts.

Tracey

> >

> >

> >

> >

> > For newbies who may not know, IRIS is the name of the trial that

first

> > studied newly diagnosed patients on Gleevec and every year at the

ASH

> > meeting, we get a follow up on how these patients are doing.

> >

> > They now have 6 years of data to report and this abstract gives

the

> > information.

> > http://www.abstracts2view.com/hem07/view.php?

nu=HEM07L1_5354 & terms=

> >

> > I'm very excited to say that for patients who have been on

Gleevec for

> > between 5 and 6 years, only 0.4% have lost their response and 0%

of

> > them have progressed to accelerated or blast phase.

> >

> > The abstract also says that no new serious adverse events have

been

> > found in the last year, meaning that Gleevec continues to be a

safe

> > drug over long term use (if you consider 6 years long term

> >

> > Take care,

> > Tracey

> >

> >

>

>

>

> --

> Marcos Perreau Guimaraes

> Suppes Brain Lab

> Ventura Hall - CSLI

> Stanford University

> 220 Panama street

> Stanford CA 94305-4101

> 650 614 2305

> 650 630 5015 (cell)

> marcospg@...

> montereyunderwater@...

> www.stanford.edu/~marcospg/

>